Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the empire HF …
…, C Kistorp, L Videbæk, MK Poulsen… - JAMA …, 2021 - jamanetwork.com
Importance Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in patients
with heart failure and a reduced ejection fraction (HFrEF). The association with cardiac …
with heart failure and a reduced ejection fraction (HFrEF). The association with cardiac …
[HTML][HTML] Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo …
J Jensen, M Omar, C Kistorp, MK Poulsen, C Tuxen… - American heart …, 2020 - Elsevier
Aims To investigate the effect of the sodium-glucose co-transporter-2 inhibitor empagliflozin
on N-terminal pro-b-type natriuretic peptide (NT-proBNP) in patients with heart failure (HF) …
on N-terminal pro-b-type natriuretic peptide (NT-proBNP) in patients with heart failure (HF) …
Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction
…, C Kistorp, L Videbæk, MK Poulsen… - Journal of the American …, 2020 - jacc.org
Background Inhibition of the sodium-glucose cotransporter-2 (SGLT2i) improves outcomes
in patients with heart failure (HF) and reduced ejection fraction (HFrEF), but the mechanism …
in patients with heart failure (HF) and reduced ejection fraction (HFrEF), but the mechanism …
[HTML][HTML] Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients
L Pedersen, M Nybo, MK Poulsen… - BMC cardiovascular …, 2014 - Springer
Background Plasma calprotectin is a potential biomarker of cardiovascular disease (CVD),
insulin resistance (IR), and obesity. We examined the relationship between plasma …
insulin resistance (IR), and obesity. We examined the relationship between plasma …
Left ventricular diastolic function in type 2 diabetes mellitus: prevalence and association with myocardial and vascular disease
MK Poulsen, JE Henriksen, J Dahl… - Circulation …, 2010 - Am Heart Assoc
Background— Although type 2 diabetes mellitus is a risk factor for developing congestive heart
failure, the mechanism leading to heart failure is unclear. We examined the prevalence of …
failure, the mechanism leading to heart failure is unclear. We examined the prevalence of …
Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab
…, M Ewertz, L Videbæk, JS Dahl, MK Poulsen… - JACC: Heart Failure, 2019 - jacc.org
Objectives : This study sought to evaluate the long-term risk of developing heart failure (HF)
in patients receiving trastuzumab therapy. Background : Trastuzumab has improved the …
in patients receiving trastuzumab therapy. Background : Trastuzumab has improved the …
[HTML][HTML] Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
J Jensen, M Omar, C Kistorp, MK Poulsen, C Tuxen… - Trials, 2019 - Springer
Background Data from recent cardiovascular outcome trials in patients with type 2 diabetes (T2D)
suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent …
suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent …
Immunogenicity of SARS‐CoV‐2 mRNA vaccine in solid organ transplant recipients
…, R Abazi, JR Davidsen, MK Poulsen… - Journal of Internal …, 2021 - Wiley Online Library
Background It is currently not well described if a two‐dose regimen of a Covid‐19 vaccine is
sufficient to elicit an immune response in solid organ transplant (SOT) recipients. Results A …
sufficient to elicit an immune response in solid organ transplant (SOT) recipients. Results A …
Automated detection of hypoglycemia-induced EEG changes recorded by subcutaneous electrodes in subjects with type 1 diabetes—the brain as a biosensor
… Juhl, Kurt Højlund, Mikael Kjær Poulsen and Peter Selmar receive consultant fees from
Hyposafe A/S. Claus Christiansen is CEO in Nordic Bioscience, an investor in Hyposafe A/S. …
Hyposafe A/S. Claus Christiansen is CEO in Nordic Bioscience, an investor in Hyposafe A/S. …
[HTML][HTML] Determinants of antibody response to a third SARS-CoV-2 mRNA vaccine dose in solid organ transplant recipients: Results from the prospective cohort study …
…, SO Lindvig, JR Davidsen, R Abazi, MK Poulsen… - Vaccines, 2022 - mdpi.com
Background: We studied factors related to humoral response in solid organ transplant (SOT)
recipients following a three-dose regimen of an mRNA-based SARS-CoV-2 vaccine. Method…
recipients following a three-dose regimen of an mRNA-based SARS-CoV-2 vaccine. Method…